Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Pharming Group to convene Extraordinary General Meeting of Shareholders Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam:...
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or...
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated...
Pharming announces public cash offer to the shareholders of Abliva AB Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product...
Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive...
Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the...
Pharming announces positive topline data in pediatric clinical trial of leniolisib Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare...
Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports third quarter 2024 financial results and provides business update Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023...
Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.002 | -0.224215246637 | 0.892 | 0.9255 | 0.887 | 3294147 | 0.91218431 | DE |
| 4 | -0.008 | -0.890868596882 | 0.898 | 0.9685 | 0.8815 | 5876960 | 0.92546703 | DE |
| 12 | 0.115 | 14.8387096774 | 0.775 | 0.9685 | 0.683 | 5982523 | 0.83703053 | DE |
| 26 | 0.122 | 15.8854166667 | 0.768 | 0.9685 | 0.6475 | 5260311 | 0.79142121 | DE |
| 52 | -0.22 | -19.8198198198 | 1.11 | 1.22 | 0.6475 | 5420680 | 0.87606605 | DE |
| 156 | 0.104 | 13.2315521628 | 0.786 | 1.419 | 0.6475 | 6036814 | 1.01796054 | DE |
| 260 | -0.56 | -38.6206896552 | 1.45 | 1.4995 | 0.6475 | 6771738 | 1.05179965 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
